Market Cap 431.29B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 24.02
Forward PE 17.22
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 6,800,932
Avg Vol 7,090,908
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 63%
Beta 0.30
Analysts Strong Sell
Price Target $263.59

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
opt_guru101
opt_guru101 Jul. 17 at 8:08 PM
$ABBV sub 250 next week...
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 17 at 7:25 PM
$SLS $ABBV $XBI " I strongly believe Gps will reach the study primary endpoint " - Dr. Tsirigotis treats more Phase 3 patients than any other doctor. 60th Event Dec 8th 2024 - IDMC Unblinded Actual MOS and IR Data from the Interim Analysis -- the SHARE PRICE LAUNCHED. 72nd Event - Dec 26th 2025 - the Share PRICE LAUNCHED 388 Days for 12 Events - 31 days Per Event 78th Event - May 11 2026 THE SHARE PRICE LAUNCHED AGAIN 136 Days for 6 Events - 1 Event Per 22 Days ... ITS BEEN 67 Days Since the the 78th ... - 80 Events are NOW IMMINENT and the CEO Just Told US ....
0 · Reply
GorillaTrades
GorillaTrades Jul. 17 at 7:11 PM
Top 3 #momentum #stocks In The GorillaTrades #portfolio This Week: Terreno Realty $TRNO +7.5%, Otter Tail $OTTR +4%, and AbbVie $ABBV +3.9%
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 17 at 7:01 PM
$SLS While we are Seeing Near Miraculous Extended Survival in the SLS Phase 3 AML Remission Maintenance Trial, Aza+VEN - Best Available Treatment (BAT) for the CONTROL ARM Patients - recently FAILED 3 Large Phase 3 AML Trials conducted by $ABBV BAT FAILED ... and Gps has proven successful in preventing relapse and extending survival, 2x 3x 4x in all Prior Trials - including 2 Phase 2 Trials for AML Remission Maintenance.
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 17 at 6:55 PM
$SLS Just ReChecking, do all you Short Scumbag Liars KNOW, Aza+VEN - Best Available Treatment (BAT) for the SLS REGAL Phase 3 CONTROL ARM Patients - recently FAILED 3 Large Phase 3 AML Trials conducted by $ABBV ? Including Failing the VIALE-M and VIALE-T Phase 3 trials for AML Remission Maintenance.??? Aza+VEN BAT for control arm Patients - also KILLED 23% of the VIALE-A Patients --- YES --- BAT for REGAL Control Patients actually Killed Nearly a quarter of the VIALE-A Patients. BAT for the SLS Control Arm Patients recently Failed 3 Large Phase 3 Trials Conducted by $ABBV ... Short Market Manipulation is offering the Investment Opportunity of Our Lifetimes. P3 Results worth 27X the Current Rigged Market Cap are Now IMMINENT. $XBI
2 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 17 at 5:05 PM
$SLS $ABBV $XBI Very Likely SLS Share Holders will be Seeing a 10x Plus ROI - Next Week. 10x and the Share Price will continue to climbing based on the True value of Gps an Immunotherapy that will Revolutionize AML Remission Maintenance. Note: there are 100,000+ US/Eu/J Acute Myeloid Leukemia Patients CURRENTLY in Remission who'll Immediately benefit from Gps -right out of the Gate Upon Approval - this year. - AML Patients - live in Fear, Each Day worried about this deadly disease returning. NO MORE. NO MORE. ABVX is a great example of the Power of Registratinal Phase 3 Results and the Impact on a small bio Share Price. b hodlin'
0 · Reply
DidYouReadThis
DidYouReadThis Jul. 17 at 4:04 PM
0 · Reply
FibonacciFortress
FibonacciFortress Jul. 17 at 2:54 PM
$ABBV received European approval for Boey® (trenibotulinumtoxinE), expanding Allergan Aesthetics’ position in the medical aesthetics market. The product is designed as a rapid-onset, short-duration neurotoxin for temporary improvement of frown lines, offering a different profile compared with traditional longer-lasting treatments. The approval adds another potential growth driver for AbbVie’s aesthetics portfolio as demand for personalized and flexible cosmetic treatments continues to expand. The next step will be watching commercial adoption and how Boey® competes in an increasingly crowded aesthetics market.
0 · Reply
69daytrader
69daytrader Jul. 17 at 2:46 PM
$ABBV 258 is a challenge
0 · Reply
focafoca99
focafoca99 Jul. 17 at 12:10 PM
$ABBV secured European approval for Boey, the first rapid-onset, short-duration neurotoxin for glabellar lines. https://www.rapidticker.com/news/abbv-allergan-aesthetics-receives-approval-for-e48ebb
0 · Reply
Latest News on ABBV
AbbVie price target raised to $260 from $230 at Citi

2026-07-15T10:21:06.000Z - 2 days ago

AbbVie price target raised to $260 from $230 at Citi


AbbVie price target raised to $260 from $230 at UBS

2026-07-13T16:30:09.000Z - 4 days ago

AbbVie price target raised to $260 from $230 at UBS


AbbVie price target raised to $300 from $258 at BMO Capital

2026-07-13T12:27:09.000Z - 4 days ago

AbbVie price target raised to $300 from $258 at BMO Capital


AbbVie price target raised to $280 from $260 at RBC Capital

2026-07-10T13:10:21.000Z - 7 days ago

AbbVie price target raised to $280 from $260 at RBC Capital


AbbVie price target raised to $276 from $234 at BofA

2026-07-10T10:31:16.000Z - 7 days ago

AbbVie price target raised to $276 from $234 at BofA


AbbVie price target raised to $295 from $260 at Wells Fargo

2026-07-10T10:20:22.000Z - 7 days ago

AbbVie price target raised to $295 from $260 at Wells Fargo


AbbVie price target raised to $280 from $260 at JPMorgan

2026-07-09T12:06:14.000Z - 8 days ago

AbbVie price target raised to $280 from $260 at JPMorgan


AbbVie price target raised to $261 from $249 at Guggenheim

2026-07-09T11:30:42.000Z - 8 days ago

AbbVie price target raised to $261 from $249 at Guggenheim


AbbVie says Q2 EPS to include unfavorable impact of 17c

2026-07-06T20:20:39.000Z - 11 days ago

AbbVie says Q2 EPS to include unfavorable impact of 17c


AbbVie price target raised to $300 from $275 at HSBC

2026-07-06T14:20:07.000Z - 11 days ago

AbbVie price target raised to $300 from $275 at HSBC


AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 21 days ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call


AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 23 days ago

AbbVie's $11 Billion Immunology Bet

APGE


AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 25 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE


AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 25 days ago

AbbVie Transcript: M&A announcement


AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 25 days ago

AbbVie Slides: M&A announcement


AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 25 days ago

AbbVie Press release: M&A announcement


AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 25 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE


AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 25 days ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE


AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 4 weeks ago

AbbVie Declares Quarterly Dividend


US FDA approves AbbVie's rare blood cancer drug

May 27, 2026, 3:33 PM EDT - 7 weeks ago

US FDA approves AbbVie's rare blood cancer drug


AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 2 months ago

AbbVie Transcript: AGM 2026


AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings Call Transcript: Q1 2026


AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings release: Q1 2026


AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Quarterly report: Q1 2026


AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 2 months ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth


AbbVie Reports First-Quarter 2026 Financial Results

Apr 29, 2026, 7:47 AM EDT - 2 months ago

AbbVie Reports First-Quarter 2026 Financial Results


opt_guru101
opt_guru101 Jul. 17 at 8:08 PM
$ABBV sub 250 next week...
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 17 at 7:25 PM
$SLS $ABBV $XBI " I strongly believe Gps will reach the study primary endpoint " - Dr. Tsirigotis treats more Phase 3 patients than any other doctor. 60th Event Dec 8th 2024 - IDMC Unblinded Actual MOS and IR Data from the Interim Analysis -- the SHARE PRICE LAUNCHED. 72nd Event - Dec 26th 2025 - the Share PRICE LAUNCHED 388 Days for 12 Events - 31 days Per Event 78th Event - May 11 2026 THE SHARE PRICE LAUNCHED AGAIN 136 Days for 6 Events - 1 Event Per 22 Days ... ITS BEEN 67 Days Since the the 78th ... - 80 Events are NOW IMMINENT and the CEO Just Told US ....
0 · Reply
GorillaTrades
GorillaTrades Jul. 17 at 7:11 PM
Top 3 #momentum #stocks In The GorillaTrades #portfolio This Week: Terreno Realty $TRNO +7.5%, Otter Tail $OTTR +4%, and AbbVie $ABBV +3.9%
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 17 at 7:01 PM
$SLS While we are Seeing Near Miraculous Extended Survival in the SLS Phase 3 AML Remission Maintenance Trial, Aza+VEN - Best Available Treatment (BAT) for the CONTROL ARM Patients - recently FAILED 3 Large Phase 3 AML Trials conducted by $ABBV BAT FAILED ... and Gps has proven successful in preventing relapse and extending survival, 2x 3x 4x in all Prior Trials - including 2 Phase 2 Trials for AML Remission Maintenance.
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 17 at 6:55 PM
$SLS Just ReChecking, do all you Short Scumbag Liars KNOW, Aza+VEN - Best Available Treatment (BAT) for the SLS REGAL Phase 3 CONTROL ARM Patients - recently FAILED 3 Large Phase 3 AML Trials conducted by $ABBV ? Including Failing the VIALE-M and VIALE-T Phase 3 trials for AML Remission Maintenance.??? Aza+VEN BAT for control arm Patients - also KILLED 23% of the VIALE-A Patients --- YES --- BAT for REGAL Control Patients actually Killed Nearly a quarter of the VIALE-A Patients. BAT for the SLS Control Arm Patients recently Failed 3 Large Phase 3 Trials Conducted by $ABBV ... Short Market Manipulation is offering the Investment Opportunity of Our Lifetimes. P3 Results worth 27X the Current Rigged Market Cap are Now IMMINENT. $XBI
2 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 17 at 5:05 PM
$SLS $ABBV $XBI Very Likely SLS Share Holders will be Seeing a 10x Plus ROI - Next Week. 10x and the Share Price will continue to climbing based on the True value of Gps an Immunotherapy that will Revolutionize AML Remission Maintenance. Note: there are 100,000+ US/Eu/J Acute Myeloid Leukemia Patients CURRENTLY in Remission who'll Immediately benefit from Gps -right out of the Gate Upon Approval - this year. - AML Patients - live in Fear, Each Day worried about this deadly disease returning. NO MORE. NO MORE. ABVX is a great example of the Power of Registratinal Phase 3 Results and the Impact on a small bio Share Price. b hodlin'
0 · Reply
DidYouReadThis
DidYouReadThis Jul. 17 at 4:04 PM
0 · Reply
FibonacciFortress
FibonacciFortress Jul. 17 at 2:54 PM
$ABBV received European approval for Boey® (trenibotulinumtoxinE), expanding Allergan Aesthetics’ position in the medical aesthetics market. The product is designed as a rapid-onset, short-duration neurotoxin for temporary improvement of frown lines, offering a different profile compared with traditional longer-lasting treatments. The approval adds another potential growth driver for AbbVie’s aesthetics portfolio as demand for personalized and flexible cosmetic treatments continues to expand. The next step will be watching commercial adoption and how Boey® competes in an increasingly crowded aesthetics market.
0 · Reply
69daytrader
69daytrader Jul. 17 at 2:46 PM
$ABBV 258 is a challenge
0 · Reply
focafoca99
focafoca99 Jul. 17 at 12:10 PM
$ABBV secured European approval for Boey, the first rapid-onset, short-duration neurotoxin for glabellar lines. https://www.rapidticker.com/news/abbv-allergan-aesthetics-receives-approval-for-e48ebb
0 · Reply
KenFaulkenberry
KenFaulkenberry Jul. 17 at 1:59 AM
$ABBV Abbvie (ABBV) Stock Analysis AbbVie is a global, research-based biopharmaceutical company engaged in the discovery, development, manufacture and sale of a broad line of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders. Is the stock price a Buy, Sell, or Hold? What is the Intrinsic Value of AbbVie (ABBV)? https://dividendvaluebuilder.com/abbvie-abbv-dividend-stock-analysis/
0 · Reply
crtlabz
crtlabz Jul. 17 at 1:07 AM
$ABBV beautiful!
0 · Reply
Merlintrader
Merlintrader Jul. 16 at 11:51 PM
REGENXBIO $RGNX Stock Hub - proposed 100 million dollar stock offering brings back dilution risk ahead of two Q3 2026 BLA paths (NAVSUNLI, RGX-202) and Q4 AbbVie retina data $ABBV $NVS https://www.merlintrader.com/regenxbio-stock-hub/
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 16 at 11:43 PM
$SLS Just Checking, does everyone KNOW, Aza+VEN - Best Available Treatment (BAT) for the SLS REGAL Phase 3 CONTROL ARM Patients - recently FAILED 3 Large Phase 3 AML Trials conducted by $ABBV ? Including Failing the VIALE-M and VIALE-T Phase 3 trials for AML Remission Maintenance.??? Aza+VEN BAT for control arm Patients - also KILLED 23% of the VIALE-A Patients --- YES --- BAT for REGAL Control Patients actually Killed Nearly a quarter of the VIALE-A Patients. BAT for the SLS Control Arm Patients recently Failed 3 Large Phase 3 Trials Conducted by $ABBV ... Short Market Manipulation is offering the Investment Opportunity of Our Lifetimes. P3 Results worth 27X the Current Rigged Market Cap are Now IMMINENT. $XBI
0 · Reply
BobJohnBuoy666
BobJohnBuoy666 Jul. 16 at 9:56 PM
$ABBV what a stud. LOOOOONG
0 · Reply
DefenseMania
DefenseMania Jul. 16 at 8:30 PM
$ABBV $AMGN $MO $VZ $GILD DANG !!! just a few of my dividend income stocks on 🔥 the compounding is INSANE !!!!!!!!!!
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 16 at 8:21 PM
$SLS $ABBV https://library.ehaweb.org/eha/2026/eha-2026/4206680/uma.borate.opti-aml.prospective.randomized.phase.2.trial.of.28.versus.14.day.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D6%2Amedia%3D3%2Ace_id%3D2934%2Aot_id%3D115581%2Amarker%3D6765
0 · Reply
fir93
fir93 Jul. 16 at 8:01 PM
$ABBV pmc 80 xd 😁
0 · Reply
liamsniperalert
liamsniperalert Jul. 16 at 7:53 PM
$ABBV @.24 | +100% 🏆 SOLD MOST , LEFT RUNNERS
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 16 at 7:35 PM
$SLS BAT for the SLS Control Arm Patients recently Failed 3 Large Phase 3 Trials Conducted by $ABBV ... Manipulation is offering the Investment Opportunity of Our Lifetimes. P3 Results worth 27X the Current Rigged Market Cap are Now IMMINENT. $XBI
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Jul. 16 at 7:08 PM
$ABBV crushing day!
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 16 at 5:47 PM
$SLS why Would $ABBV terminate a AML Remission Maintenance Phase 3 trial ? that was ongoing for 6 years and cost $500M + ? Aza VEN - Best Available Treatment - BAT - for SLS Phase 3 Control Arm Patients - in Second Remission - is toxic and Failed 3 Large AML Maintenance Trials. 80th Event and Share Price Launch is Now Imminent 66 Days in a trial where events have been occurring every 22 Days ... Be Holding when the 80th Event is Announced.
0 · Reply